

# COPD, Bronchiectasis and Asthma Longitudinal Trends

**First published:** 08/04/2026

**Last updated:** 08/04/2026

Study

Planned

## Administrative details

### EU PAS number

EUPAS1000000925

---

### Study ID

1000000925

---

### DARWIN EU® study

No

---

### Study countries

 France

 Germany

 Japan

 United States

---

### Study description

This study aims to describe recent trends in exacerbation rates among patients with COPD, asthma, and bronchiectasis, and to characterize patient demographics, disease characteristics, and clinical management practices across the included countries.

---

## Study status

Planned

## Research institutions and networks

### Institutions


#### Chiesi Farmaceutici


**First published:** 01/02/2024


**Last updated:** 01/02/2024


Institution

#### Global Database Studies, IQVIA

 Czechia

 Finland

 Germany

 Slovakia

 Spain

**First published:** 17/01/2011

**Last updated:** 31/07/2024

Institution

Other

ENCePP partner

## Contact details

### Study institution contact

Clara Sanchez c.sanchez@chiesi.com

Study contact

[c.sanchez@chiesi.com](mailto:c.sanchez@chiesi.com)

### Primary lead investigator

James Chalmers

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Actual: 08/10/2025

---

### Study start date

Planned: 10/02/2026

---

### Data analysis start date

Planned: 02/03/2026

---

### Date of final study report

Planned: 29/05/2026

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Chiesi Farmaceutici SpA

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study topic:**

Disease /health condition

---

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Disease epidemiology

#### **Data collection methods:**

**Study design:**

Non-interventional, multi-country, observational, retrospective cohort study based on secondary data

**Main study objective:**

Longitudinal trends in clinical outcomes among patients living with chronic respiratory diseases

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Medical condition to be studied**

Chronic obstructive pulmonary disease

Asthma

Bronchiectasis

## Population studied

**Short description of the study population**

Adult population with COPD

Adult population with bronchiectasis

Adults and children with asthma

### **Age groups**

- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)
- Adults (18 to < 65 years)
  - Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
- Elderly ( $\geq$  65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)

## Study design details

### **Setting**

Non-interventional, multi-country, observational, retrospective cohort study based on secondary data from databases in France, Germany, the USA, and Japan. Selected study period is 2017 - 2024.

The study will include patients who: are alive for at least one day during the study period (1 January 2017 to 31 December 2024) and have at least 12 months of continuous observation in the analysis set prior to their earliest qualifying diagnosis of each study condition (asthma, COPD, or bronchiectasis). Additionally, disease specific inclusion and exclusion criteria will be considered for each one of the cohorts

---

### **Outcomes**

Primary outcomes are annualized exacerbation rates, incidence of LRTI, and patients' characteristics at baseline

---

## Data analysis plan

Four country-specific analysis sets will be defined, corresponding to the four contributing data sources: France, Germany, the United States, and Japan. Each analysis set will include all eligible patients from the respective data source.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

Longitudinal Patient Data - France

IQVIA Disease Analyzer Germany

---

### Data source(s), other

PharMetrics Plus (USA), Japan claims database (IQVIA)

---

### Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

## **CDM mapping**

Yes

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No